Sustainability & ESG in Medical Devices: Regulatory Drivers, Circular Economy, and Industry Best Practices

Why Sustainability Matters in MedTech

Healthcare is one of the largest contributors to global environmental damage — and the medical device industry sits at the center of that problem. The healthcare sector accounts for approximately 4.4% of global net greenhouse gas emissions, according to the Health Care Without Harm "Health Care Climate Footprint" report. If the global healthcare sector were a country, it would be the fifth-largest emitter on the planet, behind only China, the United States, the EU, and India.

Medical devices contribute to this footprint at every stage: raw material extraction, manufacturing, sterilization, packaging, transportation, clinical use, and disposal. The numbers are staggering. Hospitals in the United States alone generate over 5.9 million tons of waste annually, and a significant share of that waste comes from single-use medical devices, packaging, and disposable components. A single surgical procedure can generate 20-30 pounds of waste, much of it plastic that ends up in landfills or incinerators.

Several converging forces are now making sustainability a strategic imperative — not a nice-to-have — for medical device companies:

• Regulatory pressure — The EU Corporate Sustainability Reporting Directive (CSRD), SEC climate disclosure rules, and California SB 253/261 are creating mandatory reporting obligations that directly affect medtech companies above certain thresholds.
• Investor ESG demands — Institutional investors managing trillions in assets now routinely screen for ESG performance. BlackRock, Vanguard, and State Street have all integrated ESG factors into their investment processes. MedTech companies with poor environmental track records face higher cost of capital and reduced access to funding.
• Hospital procurement criteria — Healthcare systems are increasingly incorporating sustainability into procurement decisions. Kaiser Permanente, the NHS, and many EU hospital networks now include environmental criteria in their device purchasing evaluations. A 2024 survey by Practice Greenhealth found that over 70% of US health systems consider environmental impact when making purchasing decisions.
• Talent acquisition — Younger professionals increasingly choose employers based on purpose and environmental responsibility. Companies with credible sustainability programs have a measurable advantage in recruiting and retention.
• Cost reduction — Energy efficiency, waste reduction, and material optimization directly reduce operating costs. Sustainability and profitability are not in opposition — they are increasingly aligned.

The business reality: Sustainability is no longer a corporate communications exercise. It is a regulatory compliance obligation, a procurement requirement, a cost management strategy, and an investor expectation — all at once. Companies that treat it as optional will face tangible commercial consequences.

Regulatory Drivers

The regulatory landscape for sustainability in medtech has transformed dramatically since 2023. What was once voluntary is rapidly becoming mandatory.

EU Corporate Sustainability Reporting Directive (CSRD)

The CSRD, which entered into force on January 5, 2023, is the most significant sustainability reporting regulation globally. It requires companies meeting certain thresholds to report detailed sustainability information following the European Sustainability Reporting Standards (ESRS).

Who is affected in medtech:

• Large EU-based companies (including subsidiaries) with 250+ employees, EUR 50M+ revenue, or EUR 25M+ total assets (two of three criteria)
• Non-EU companies with EUR 150M+ net turnover in the EU and at least one EU subsidiary or branch meeting specified thresholds
• Listed SMEs (with a transitional opt-out until 2028)

The ESRS cover environmental, social, and governance topics in granular detail. For environmental reporting, companies must disclose climate change impacts (ESRS E1), pollution (ESRS E2), water and marine resources (ESRS E3), biodiversity and ecosystems (ESRS E4), and resource use and circular economy (ESRS E5). This is not check-the-box reporting — the ESRS require double materiality assessments, quantitative metrics, forward-looking targets, and third-party assurance.

For medtech companies selling into the EU, CSRD compliance is not optional. The reporting obligations cascade through value chains, meaning even companies not directly subject to CSRD will be asked for sustainability data by their customers and partners who are.

EU Green Deal and Circular Economy Action Plan

The European Green Deal aims to make the EU climate-neutral by 2050. The Circular Economy Action Plan (CEAP) — a core pillar of the Green Deal — specifically targets product sustainability, waste reduction, and resource efficiency. Medical devices, as "resource-intensive" products, fall within scope.

Key elements affecting medtech:

• Waste Framework Directive revisions targeting healthcare waste streams
• Packaging and Packaging Waste Regulation (PPWR) imposing recycled content mandates and packaging minimization requirements
• Extended Producer Responsibility (EPR) schemes that may extend to medical device categories

EU Eco-design for Sustainable Products Regulation (ESPR)

The ESPR, adopted in 2024, extends eco-design requirements beyond energy-related products to virtually all physical products placed on the EU market. While medical devices have a conditional exemption under the regulation (Article 1(2)(h) provides that devices covered by EU MDR and IVDR are excluded from ESPR requirements for aspects already covered by those regulations), the ESPR introduces the Digital Product Passport (DPP) — a concept that may eventually apply to medical devices through MDR/IVDR amendments or delegated acts.

The DPP would require products to carry machine-readable information about their materials, manufacturing, repairability, recyclability, and carbon footprint. The European Commission has signaled interest in extending DPP concepts to the healthcare sector.

FDA Environmental Assessment Requirements

In the United States, the FDA has long required Environmental Assessments (EAs) under the National Environmental Policy Act (NEPA) for certain regulatory actions. Most medical device submissions qualify for categorical exclusions under 21 CFR 25.34, meaning no EA is required. However, devices involving new sterilization methods, novel materials with environmental release potential, or processes with significant environmental impact may trigger EA requirements.

More significantly, the FDA has increasingly signaled interest in sustainability through several channels:

• The Innovation Challenge for Reducing EtO Emissions program, encouraging development of alternative sterilization technologies
• Guidance on reprocessing of single-use devices, which supports waste reduction
• The FDA Environmental Sustainability initiative, which includes internal operations and regulatory approaches

California SB 253 and SB 261

California's Climate Corporate Data Accountability Act (SB 253) and Climate-Related Financial Risk Act (SB 261) affect any company doing business in California with annual revenues exceeding $1 billion (SB 253) or $500 million (SB 261). Given that virtually every major medtech company operates in California, these laws have broad reach.

SB 253 requires reporting of Scope 1, 2, and 3 greenhouse gas emissions following the GHG Protocol. SB 261 requires reporting on climate-related financial risks following TCFD recommendations. Both laws have survived legal challenges and are being implemented, with reporting deadlines phased in through 2026-2027.

SEC Climate Disclosure Rules

The SEC's climate-related disclosure rules, finalized in March 2024 (though subject to ongoing litigation and stays), require public companies to disclose material climate-related risks, greenhouse gas emissions (Scope 1 and 2), and the financial effects of severe weather events and climate-related activities. While Scope 3 reporting was ultimately excluded from the final rule, the direction of travel is clear: climate disclosure is becoming a standard component of public company reporting in the United States.

Regulation	Jurisdiction	Who Is Affected	Key Requirement	Timeline
EU CSRD	EU	Large companies, non-EU companies with significant EU turnover	Double materiality sustainability reporting per ESRS	Phased: 2024-2029
SB 253	California/US	Companies with $1B+ revenue doing business in CA	Scope 1, 2, 3 GHG emissions disclosure	2026-2027
SB 261	California/US	Companies with $500M+ revenue doing business in CA	Climate-related financial risk reporting	2026
SEC Climate Rules	US	US public companies	Material climate risks, Scope 1 & 2 emissions	Phased (subject to litigation)
EU ESPR	EU	Products on EU market (limited medical device exemption)	Eco-design, Digital Product Passport	2025+ (delegated acts)
EU PPWR	EU	Packaging on EU market	Recycled content, packaging minimization	2025-2030

EU MDR and Environmental Considerations

The EU Medical Device Regulation (EU 2017/745) is not typically thought of as environmental legislation, but it contains several provisions directly relevant to sustainability.

Annex I General Safety and Performance Requirements (GSPR)

Several GSPRs address environmental safety and the interaction between devices, patients, and the broader environment:

• GSPR 10.1 requires that devices be designed and manufactured in such a way as to reduce risks related to substances or particles that may be released from the device, including wear debris, degradation products, and processing residues. This implicitly encourages material choices that minimize environmental contamination.
• GSPR 10.4 addresses restrictions on hazardous substances, specifically CMR (carcinogenic, mutagenic, reprotoxic) substances and endocrine disruptors — particularly phthalates such as DEHP and other substances listed under Annex I, Section 10.4.1. Manufacturers must justify the use of such substances or substitute them.
• GSPR 10.4.1(c) requires that where devices contain CMR or endocrine-disrupting substances above 0.1% w/w, the device labeling must identify these substances. This transparency requirement drives material substitution.
• GSPR 14.7 requires information to be provided to users about safe disposal of the device and any related waste.

REACH and RoHS Applicability

Medical devices exist at the intersection of product safety regulation and chemical regulation:

• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) — Regulation (EC) 1907/2006 applies to medical devices insofar as they contain chemical substances. The Substances of Very High Concern (SVHC) Candidate List is particularly relevant. Medical device manufacturers must track SVHC content, communicate down the supply chain, and prepare for potential authorization requirements. Several phthalates (DEHP, DBP, BBP, DIBP) commonly used as plasticizers in PVC medical devices are on the SVHC list.
• RoHS (Restriction of Hazardous Substances) — Directive 2011/65/EU restricts lead, mercury, cadmium, hexavalent chromium, PBBs, and PBDEs in electrical and electronic equipment. Medical devices were previously exempt; as of July 22, 2014 (in vitro diagnostic devices from July 22, 2016), they fall within scope (with certain exemptions for implantable and Class IIb/III active devices through ongoing review). Compliance with RoHS requires material declarations from all component suppliers and testing protocols for restricted substances.

WEEE Directive Compliance for Electronic Medical Devices

The Waste Electrical and Electronic Equipment (WEEE) Directive (2012/19/EU) is a critical but often overlooked regulation for medical device manufacturers. WEEE II brought medical devices and in vitro diagnostic devices fully within scope, requiring producers of electrical and electronic medical equipment to take responsibility for end-of-life collection, treatment, and recycling.

Key WEEE obligations for medtech:

• Producer registration — Manufacturers placing electronic medical devices on the EU market must register with national WEEE compliance schemes in each Member State where they sell
• Collection and recovery targets — EU Member States must collect 65 tonnes of e-waste for every 100 tonnes of EEE placed on the market over the preceding three years. Medical device producers contribute to meeting these targets through compliance scheme fees
• Design for recyclability — The directive mandates that producers design electronic products with easier recycling in mind, encouraging modular construction, material marking, and avoidance of hazardous substances that complicate recycling
• Reporting obligations — Producers must report amounts of EEE placed on the market, collected, recycled, and recovered

Important exemptions: Active implantable medical devices and medical devices (including IVDs) that are expected to be infective prior to end of life are excluded from WEEE II scope. However, the vast majority of electronic medical devices — patient monitors, imaging systems, infusion pumps, diagnostic analyzers, surgical navigation systems — are fully within scope.

For medtech companies, WEEE compliance creates both obligations and opportunities. The collection and recycling infrastructure required by WEEE aligns naturally with circular economy strategies, and companies that design devices for easier disassembly and material recovery gain advantages in both WEEE compliance costs and sustainability performance.

Biocompatibility and Environmental Safety Overlap

ISO 10993-17 (chemical characterization of medical device materials) and ISO 10993-18 (chemical characterization of materials) drive analysis of extractables and leachables. These same chemicals, when released into the environment through device disposal, create environmental contamination pathways. There is increasing recognition that biocompatibility assessment and environmental safety assessment share a common analytical foundation — the chemicals that concern toxicologists also concern environmental scientists.

Circular Economy in Medical Devices

The linear "take-make-dispose" model is deeply entrenched in medtech, but the circular economy framework — designing out waste, keeping materials in use, and regenerating natural systems — is gaining traction.

Single-Use vs. Reusable: The Central Debate

The shift from reusable to single-use devices over the past three decades was driven by infection control concerns, convenience, and reprocessing cost avoidance. But the environmental cost has been enormous. Single-use devices now account for a large and growing share of healthcare waste.

The debate is not simple. Single-use devices eliminate reprocessing risk, simplify logistics, and often reduce per-procedure reprocessing labor costs. But they generate vastly more waste, consume more raw materials, and have higher lifecycle carbon footprints than well-designed reusable alternatives.

Key considerations:

Factor	Single-Use	Reusable
Infection risk	Eliminated (no reprocessing)	Managed through validated cleaning/sterilization
Waste generation	High (device discarded after one use)	Low (device used hundreds/thousands of times)
Carbon footprint per use	High (manufacturing + disposal each time)	Lower over lifecycle (amortized manufacturing)
Water consumption	Lower per use (no cleaning)	Higher per use (cleaning and sterilization)
Capital cost	None (consumable model)	High (device + reprocessing infrastructure)
Total lifecycle cost	Often higher over time	Often lower over time

Emerging trend: Several large medtech companies are redesigning devices with modular architectures — single-use patient-contact components combined with reusable handles, motors, and electronics. This "hybrid" approach captures the infection control benefits of single-use while dramatically reducing waste and material consumption.

Reprocessing of Single-Use Devices

Reprocessing — collecting used single-use devices, cleaning, testing, resterilizing, and returning them to clinical service — is a significant sustainability strategy with complex regulatory implications.

FDA approach (United States): Under FDA regulation, reprocessed single-use devices are treated as new devices. Third-party reprocessors must submit 510(k)s or PMAs, register as manufacturers, comply with QSR/QMSR requirements, and perform validation testing. The FDA has cleared reprocessing for numerous device categories including certain laparoscopic instruments, electrophysiology catheters, compression sleeves, ultrasound transducer covers, and surgical saw blades. The Association of Medical Device Reprocessors (AMDR) estimates that reprocessing diverts over 10 million pounds of medical device waste from landfills annually in the US alone.

EU approach: The EU MDR (Article 17) permits Member States to allow reprocessing of single-use devices provided that national legislation permits it, the reprocessor meets manufacturer obligations, and the reprocessed device complies with the relevant CS (Common Specifications). In practice, only a few EU Member States (notably Germany) have actively permitted reprocessing, and the landscape is fragmented.

Refurbishment and Remanufacturing

Large capital equipment — imaging systems, surgical robots, patient monitors — is increasingly refurbished or remanufactured:

• Refurbishment involves restoring a device to its original specifications through cleaning, repair, replacement of worn components, and functional testing. The device retains its original clearance/approval.
• Remanufacturing involves a more extensive process that may include design modifications, new components, and updated software. Remanufactured devices may require new regulatory submissions.

Companies like Philips, GE HealthCare, Siemens Healthineers, and Stryker operate large refurbishment programs. Philips' refurbished systems (branded "Philips Diamond Select") reportedly reduce material use by up to 90% compared to manufacturing new systems. Siemens Healthineers' "Proven Excellence" refurbished equipment program extends equipment lifecycles by 5-10 years.

Packaging Reduction

Medical device packaging contributes significantly to hospital waste. Sustainability-focused packaging strategies include:

• Right-sizing — Eliminating empty space in packaging to reduce material usage and transportation volume
• Material substitution — Replacing PVC blister packs with recyclable alternatives (PET, PP)
• Tyvek optimization — Using lighter-weight Tyvek or alternative breathable materials for sterile barrier packaging
• Instruction for Use (IFU) digitization — Replacing printed IFUs with electronic IFUs (eIFUs), which the EU MDR explicitly permits under Article 7 of Regulation (EU) 2021/2226 for certain device classes
• Shelf unit reduction — Redesigning surgical kits to include only necessary components rather than oversized trays with unused instruments

Lifecycle Assessment (LCA) for Medical Devices

Lifecycle assessment is the structured, quantitative method for evaluating the environmental impacts of a product across its entire life — from raw material extraction ("cradle") to final disposal ("grave"). For medical devices, LCA is both a decision-making tool and increasingly a regulatory compliance tool.

ISO 14040/14044 Framework

The foundational standards for LCA are ISO 14040:2006 (Principles and Framework) and ISO 14044:2006 (Requirements and Guidelines). Together, they define the four phases of LCA:

1. Goal and scope definition — Define the purpose, system boundaries, functional unit, and allocation procedures
2. Life cycle inventory (LCI) — Quantify all material and energy inputs and outputs across the lifecycle
3. Life cycle impact assessment (LCIA) — Translate inventory data into environmental impact categories (global warming potential, acidification, eutrophication, resource depletion, etc.)
4. Interpretation — Analyze results, identify significant issues, draw conclusions, and make recommendations

Scope and Boundaries for Device LCA

Defining the system boundary is the most critical — and most contentious — step in medical device LCA. The boundary determines what is included in the analysis and what is excluded.

A comprehensive device LCA should include:

• Raw material extraction and processing — Mining, refining, polymer production, metal smelting
• Component manufacturing — Machining, molding, assembly, surface treatment
• Packaging manufacture — Sterile barrier system, protective packaging, labeling
• Sterilization — Energy, consumables, emissions (EtO, irradiation source production)
• Transportation — Raw materials to manufacturing, finished goods to sterilizers, sterilized products to distribution centers, distribution to hospitals
• Use phase — Energy consumption (for powered devices), consumables, cleaning and reprocessing (for reusable devices), water
• End of life — Collection, waste segregation, transportation to disposal, landfill, incineration, recycling, or other treatment

The functional unit — the reference basis for comparison — must be carefully chosen. For a surgical instrument, the functional unit might be "one surgical procedure" or "1,000 procedures." For an infusion pump, it might be "one patient-day of infusion therapy." The functional unit determines whether a single-use device has a higher or lower impact than a reusable alternative over the same clinical service.

Carbon Footprint Calculation

Carbon footprint (measured in kg CO2-equivalent) is the most commonly reported LCA metric for medical devices. The GHG Protocol and ISO 14067 provide frameworks for product carbon footprinting.

Key impact contributors for a typical medical device:

Lifecycle Phase	Typical Contribution to Carbon Footprint
Raw materials and component manufacturing	30-60%
Sterilization	5-15%
Packaging	5-10%
Transportation and logistics	5-15%
Use phase (powered devices)	10-40% (dominant for imaging, monitoring)
End of life	3-10%

For powered devices (imaging systems, patient monitors, surgical robots), the use phase dominates the lifecycle carbon footprint — a CT scanner running for 10 years consumes enormous amounts of electricity. For single-use consumables, material extraction and manufacturing dominate. This distinction fundamentally shapes where sustainability efforts should be focused.

Sustainable Design and Materials

Design decisions made in the earliest stages of product development lock in 80% or more of a product's lifecycle environmental impact. Sustainable design is not a bolt-on — it must be integrated into the design control process from the beginning.

Bio-Based and Biodegradable Polymers

Research into bio-based polymers for medical devices has accelerated, though adoption remains limited due to biocompatibility, mechanical property, and regulatory qualification challenges:

• Polylactic acid (PLA) — Derived from corn starch or sugarcane, PLA is used in some non-implantable, non-sterile applications and in absorbable sutures and fixation devices
• Polyhydroxyalkanoates (PHAs) — Produced by bacterial fermentation, PHAs offer biodegradability and biocompatibility but are significantly more expensive than conventional polymers
• Bio-based polyethylene — Chemically identical to fossil-derived PE but made from sugarcane ethanol; used in packaging applications where a "drop-in" replacement is needed
• Cellulose-based materials — Emerging applications in packaging, wound care, and tissue engineering scaffolds

Critical caveat: Biodegradability is not always desirable in medical devices. A device that degrades prematurely in the body or during shelf life creates a safety risk. The regulatory pathway for novel bio-based materials requires the same rigorous biocompatibility testing (ISO 10993 series) as any other material. "Green" does not automatically mean "safe."

Material Substitution Strategies

Several material substitutions are gaining traction across the industry:

• PVC-free IV bags and tubing — Replacing PVC/DEHP with polyolefin alternatives (polyethylene, polypropylene). Baxter, B. Braun, and ICU Medical have all introduced PVC-free IV solutions.
• Phthalate-free formulations — Substituting DEHP with alternative plasticizers (DEHT, TOTM, citrate esters) in flexible PVC devices. EU MDR Annex I Section 10.4 is a direct driver.
• Recycled-content packaging — Using post-consumer recycled (PCR) PET or HDPE for secondary and tertiary packaging (not typically for primary sterile barrier packaging due to particulate concerns)
• Reduced material intensity — Miniaturization, thin-walling, and topology optimization to achieve the same functional performance with less material

Design for Disassembly

Designing devices so they can be easily disassembled at end of life facilitates material recovery and recycling. Principles include:

• Minimizing the number of different materials in a device
• Using snap-fits instead of adhesive bonds where possible
• Marking all plastic components with material identification codes (ISO 11469)
• Avoiding inseparable multi-material assemblies where not functionally necessary
• Providing disassembly instructions for waste processors

Manufacturing Sustainability

Medical device manufacturing is energy-intensive and resource-intensive. Cleanroom operations, sterilization, precision machining, and quality testing all consume significant energy and materials. Manufacturing is also where medtech companies have the most direct operational control — making it the natural starting point for sustainability improvements.

Energy Efficiency and ISO 50001

ISO 50001 (Energy Management Systems) provides a systematic framework for improving energy performance. For medical device manufacturers, energy efficiency opportunities include:

• HVAC optimization — Cleanrooms consume 10-100 times more energy per square foot than standard office space, with HVAC systems (air handling, filtration, temperature control) accounting for 60-70% of cleanroom energy use. Variable-speed drives, demand-controlled ventilation, and energy recovery systems can reduce HVAC energy consumption by 20-40%.
• Compressed air systems — Compressed air is one of the most expensive utilities in manufacturing. Leak detection and repair programs, pressure optimization, and variable-speed compressors can reduce compressed air energy consumption by 20-30%.
• Lighting — LED retrofits with occupancy sensors and daylight harvesting provide 50-70% energy savings over fluorescent systems.
• Process optimization — Reducing machine idle time, optimizing batch sizes, and scheduling energy-intensive processes during off-peak hours.

Renewable Energy Adoption

Many medtech companies have committed to renewable energy targets:

• Medtronic has committed to 100% renewable electricity by 2030 (RE100 member)
• Philips achieved 100% renewable electricity for all operations in 2020
• Boston Scientific targets 100% renewable electricity by 2030
• BD (Becton, Dickinson) has committed to 100% renewable electricity by 2030

Procurement strategies include on-site solar, Power Purchase Agreements (PPAs), renewable energy certificates (RECs), and virtual PPAs. The choice of instrument affects both cost and the credibility of environmental claims — on-site generation and long-term PPAs are generally considered more impactful than unbundled RECs.

Waste Minimization

Manufacturing waste reduction strategies relevant to medtech:

• Lean manufacturing — The elimination of waste (muda) in lean methodology aligns directly with environmental sustainability. Reducing overproduction, defects, excess inventory, and unnecessary transportation simultaneously improves efficiency and environmental performance.
• Solvent reduction — Substituting organic solvents with aqueous cleaning solutions, implementing closed-loop solvent recovery, and optimizing solvent usage in bonding and coating processes.
• Yield improvement — Reducing scrap rates through statistical process control, design of experiments, and process capability improvement directly reduces material waste.
• Water conservation — Closed-loop cooling systems, water recycling for cleaning operations, and condensate recovery from steam systems.

Water Stewardship

Water is a critical but often under-addressed dimension of manufacturing sustainability. Medical device manufacturing is water-intensive — cleanroom operations, ultrasonic cleaning, rinsing, steam sterilization, and cooling systems all consume significant volumes of water. Companies operating in water-stressed regions face particular risk as climate change intensifies competition for scarce water resources.

A comprehensive water stewardship program goes beyond simple conservation:

• Water risk assessment — Use tools such as the WRI Aqueduct Water Risk Atlas or WWF Water Risk Filter to assess water stress at each manufacturing site. Identify sites in high or extremely high water-stress basins as priorities for intervention.
• Water balance mapping — Map all water inputs, uses, and outputs across manufacturing operations. Identify the largest consumers (typically cleanroom HVAC humidification, cleaning/rinsing, cooling towers, and steam generation) and prioritize reduction efforts.
• Water recycling and reuse — Implement closed-loop systems for rinse water, cooling water, and condensate. Reverse osmosis reject water (a common waste stream in facilities producing purified or WFI-grade water) can be recovered for non-critical uses such as cooling tower makeup, landscaping, or toilet flushing.
• Wastewater quality management — Ensure that manufacturing wastewater meets discharge standards and does not introduce harmful chemicals (solvents, heavy metals, surfactants) into local water systems. Pre-treatment systems may be necessary for sites discharging to municipal wastewater treatment.
• Water neutrality targets — Some medtech companies, including BD (Becton, Dickinson), have committed to water neutrality in water-stressed regions — balancing water consumption with watershed restoration, community water access projects, or water efficiency programs.

The Alliance for Water Stewardship (AWS) Standard provides an internationally recognized framework for responsible water management. ISO 46001 (Water Efficiency Management Systems) offers a systematic approach similar to ISO 50001 for energy.

For ESG reporting, water metrics are a required disclosure under ESRS E3 (Water and Marine Resources), CDP Water Security questionnaires, and GRI 303 (Water and Effluents). Companies that cannot demonstrate effective water management face negative ESG ratings and, increasingly, procurement disadvantages with sustainability-conscious healthcare customers.

Sterilization and Environmental Impact

Sterilization is a critical manufacturing step for most medical devices — and it carries significant environmental implications. The choice of sterilization method directly affects energy consumption, emissions, and waste.

Ethylene Oxide (EtO) Emissions and EPA Regulations

Ethylene oxide sterilizes approximately 50% of all medical devices worldwide. It is also classified by the EPA as a carcinogenic hazardous air pollutant (HAP). The tension between EtO's indispensability and its environmental/health risks has made sterilization one of the most contentious sustainability issues in medtech.

Key regulatory developments:

• The EPA's 2024 final rule on EtO emissions from commercial sterilization facilities significantly tightened emission limits, requiring facilities to achieve 99.19% or greater ethylene oxide emission reduction. This rule imposes substantial capital expenditure requirements on sterilization facilities for emission control equipment (catalytic oxidizers, scrubbers, enclosed routing of all emission points).
• Several states, including Illinois, Georgia, and Colorado, have enacted or proposed state-level EtO emission regulations that are in some cases more stringent than federal requirements.
• Community opposition to EtO sterilization facilities has led to facility closures and permitting challenges, creating capacity concerns for the industry.

Environmental Comparison of Sterilization Methods

Method	Energy Use	Emissions/Waste	Material Compatibility	Penetration	Throughput
Ethylene oxide (EtO)	Moderate	EtO emissions (carcinogen), CO2	Excellent (nearly universal)	Excellent	High
Gamma irradiation (Co-60)	Low (during use)	Radioactive source disposal, transportation risk	Good (some polymer degradation)	Excellent	Very high
E-beam irradiation	High (electricity)	Minimal direct emissions	Good (some polymer degradation)	Limited (depth-dependent)	High
X-ray irradiation	High (electricity)	Minimal direct emissions	Good (similar to gamma)	Excellent	Moderate-high
Steam autoclave	Moderate	Water/energy consumption	Limited (heat/moisture sensitive devices excluded)	Good	Moderate
Vaporized H2O2 (VHP)	Low	Water and oxygen byproducts (benign)	Limited (cellulose incompatible)	Limited	Low-moderate
Nitrogen dioxide (NO2)	Low	Minimal at validated levels	Emerging data	Good	Low-moderate
Supercritical CO2	Moderate	CO2 release (can use captured CO2)	Emerging data	Emerging data	Low

Industry trajectory: The long-term trend is diversification away from EtO dominance. E-beam and X-ray are gaining share for compatible devices, VHP is expanding for surface sterilization and some low-bioburden devices, and novel methods (NO2, supercritical CO2) are in various stages of validation and regulatory acceptance. However, EtO will remain essential for complex, multi-material, long-lumen devices for the foreseeable future.

Greening the Operating Room

Operating rooms are the most resource-intensive environment in any hospital — consuming three to six times more energy per square foot than standard hospital spaces and generating over 30% of total hospital waste and approximately two-thirds of regulated medical waste. For medical device manufacturers, understanding the OR waste problem is critical because devices and their packaging are the primary contributors.

The Scale of OR Waste

A single surgical procedure can generate 20-30 pounds of waste. Studies estimate that up to 74% of OR waste is potentially recyclable, yet most of it ends up in regulated medical waste streams (red bags) due to a lack of segregation protocols, staff education, and infrastructure. The financial impact is significant: regulated medical waste costs hospitals 5-10 times more to dispose of than standard recyclable waste.

Leading health systems have demonstrated that targeted OR sustainability programs deliver substantial savings. The Cleveland Clinic saved over $4 million in a single year through Practice Greenhealth's Greening the OR strategies. UCLA Health's Greening the Operating Room program has implemented waste segregation, recycled blue wrap, and preference card optimization to dramatically reduce OR waste volumes.

Anesthetic Gas Emissions

Volatile anesthetic gases represent a surprisingly large and often overlooked source of greenhouse gas emissions in healthcare. Inhaled anesthetics are potent greenhouse gases with atmospheric lifetimes measured in years to over a century:

Anesthetic Agent	Global Warming Potential (GWP100, relative to CO2)	Atmospheric Lifetime
Desflurane	2,540	14 years
Isoflurane	539	3.2 years
Nitrous oxide (N2O)	273	114 years
Sevoflurane	144	1.1 years

To put this in perspective: one hour of desflurane use at standard flow rates is equivalent to driving a car for approximately 400 miles in CO2-equivalent emissions. Nitrous oxide has nearly 300 times the global warming potential of CO2 and persists in the atmosphere for over a century.

What leading institutions are doing:

• Eliminating desflurane — Loma Linda University Health and many European hospitals have removed desflurane from their formularies entirely, switching to sevoflurane (which has 18 times lower GWP)
• Decommissioning piped N2O — Multiple health systems have eliminated centrally piped nitrous oxide, using portable cylinders only when clinically necessary
• Low-flow anesthesia — Reducing fresh gas flow rates from 2-3 L/min to 0.5-1 L/min can reduce anesthetic gas consumption (and emissions) by 50-75%. The Hospital of the University of Pennsylvania reduced greenhouse gas emissions by the equivalent of 30 metric tons of CO2 in a single quarter through low-flow protocols alone
• Anesthetic gas capture — Emerging technologies capture exhaled anesthetic gases for reuse or destruction rather than venting them to the atmosphere

Why this matters for device companies: Anesthesia delivery systems, ventilators, and gas management devices are medical devices. Manufacturers of these systems have a direct role in enabling or hindering sustainability — through low-flow capable machine design, integrated gas capture compatibility, and real-time consumption monitoring displays that nudge clinicians toward lower environmental impact.

Preference Card Optimization

Surgical preference cards — the lists specifying which supplies and devices should be opened for each surgeon and procedure type — are a major source of waste. Preference cards are frequently outdated, containing items that are routinely opened but rarely used. Studies have found that 30-40% of items opened for surgical procedures go unused and must be discarded.

Device manufacturers can support preference card optimization by:

• Providing procedure-specific minimum kit configurations
• Offering modular kit options that allow customization without excess
• Supporting digital preference card management systems
• Designing packaging that allows partial opening without compromising sterility of remaining items

OR Recycling Programs

Key recyclable waste streams from the OR include:

• Blue surgical wrap (polypropylene) — One of the largest-volume recyclable materials in the OR. Multiple companies now offer blue wrap recycling programs that convert it into plastic lumber, automotive parts, or new packaging
• Rigid sterilization containers — Reusable alternatives to single-use blue wrap that eliminate wrapping waste entirely
• Clean plastics — PVC, PE, and PP packaging from pre-operative setup
• Paper and cardboard — Outer packaging and documentation
• Metals — Surgical instrument components, implant packaging, wire

Supply Chain Sustainability

For most medtech companies, Scope 3 (supply chain) emissions represent 70-90% of total greenhouse gas emissions. Manufacturing sites and direct operations (Scope 1 and 2) are important, but the supply chain is where the largest environmental impact lies — and where control is most difficult.

Scope 3 Emissions Management

The GHG Protocol defines 15 categories of Scope 3 emissions. For medical device companies, the most significant categories are typically:

1. Purchased goods and services (Category 1) — Raw materials, components, contract manufacturing
2. Capital goods (Category 2) — Manufacturing equipment, facilities
3. Upstream transportation (Category 4) — Inbound logistics
4. Downstream transportation (Category 9) — Distribution to hospitals/customers
5. Use of sold products (Category 11) — Energy consumed by powered devices during their use phase
6. End-of-life treatment (Category 12) — Disposal of sold devices

Measuring Scope 3 emissions requires data from suppliers — data that is often incomplete, inconsistent, or unavailable. Most companies start with spend-based estimation methods (using economic input-output models) and progressively improve data quality through supplier engagement.

Supplier Sustainability Audits

Leading medtech companies are integrating sustainability criteria into supplier qualification and ongoing monitoring:

• Supplier codes of conduct incorporating environmental requirements
• Self-assessment questionnaires covering energy management, emissions, waste, water, and hazardous substance management
• On-site sustainability audits — often combined with quality audits to reduce audit burden
• CDP Supply Chain program participation — requesting suppliers disclose environmental data through the Carbon Disclosure Project platform
• EcoVadis or similar third-party sustainability rating platforms for standardized supplier scoring

Conflict Minerals

Medical devices frequently contain tantalum, tin, tungsten, and gold (3TG) — minerals that may originate from conflict-affected regions, particularly the Democratic Republic of Congo and adjoining countries.

US requirements (Dodd-Frank Act, Section 1502): SEC-registered companies must conduct reasonable country of origin inquiries and due diligence for 3TG minerals in their products, and file Form SD (Specialized Disclosure) with conflict minerals reports. While enforcement emphasis has fluctuated, the reporting requirement remains in effect.

EU Conflict Minerals Regulation (EU 2017/821): Requires EU importers of 3TG above specified thresholds to conduct supply chain due diligence consistent with OECD guidelines. The regulation applies directly to importers of minerals and metals, but the due diligence obligations cascade through supply chains to downstream users, including device manufacturers.

Responsible sourcing beyond 3TG: The scope of responsible sourcing is expanding to include cobalt (used in batteries for powered medical devices), mica, and other minerals associated with human rights and environmental risks. The EU Corporate Sustainability Due Diligence Directive (CSDDD) will further formalize these obligations.

Green Procurement: How Healthcare Buyers Are Driving Change

Perhaps the most powerful market force driving sustainability in medtech is the purchasing decisions of healthcare systems themselves. Hospitals and health networks are increasingly embedding environmental criteria into procurement, creating direct commercial consequences for device companies that cannot demonstrate sustainability performance.

NHS Net Zero Supplier Requirements (United Kingdom)

The UK National Health Service (NHS) has the most advanced healthcare green procurement program globally. The NHS has committed to reaching net zero for direct emissions (Scope 1 and 2) by 2040 and net zero for supply chain emissions by 2045. Since an estimated 60% of the NHS's carbon footprint comes from its supply chain, supplier engagement is central to the strategy.

Key milestones that directly affect medical device suppliers:

• April 2023 — All NHS contracts above GBP 5 million per year require suppliers to publish a Carbon Reduction Plan (CRP) covering UK Scope 1, 2, and a subset of Scope 3 emissions
• April 2024 — CRP requirement extended to all NHS procurements, regardless of contract size or value
• April 2027 — Suppliers must publish a CRP covering global Scope 1, 2, and 3 emissions aligned with the NHS net zero target
• April 2028 — The NHS will introduce product-level carbon footprinting requirements for individual products supplied to the NHS
• Ongoing — A minimum 10% net zero and social value weighting is applied to all NHS procurement evaluations

For medical device companies selling into the UK market, these are not aspirational guidelines — they are contractual requirements. Companies without published Carbon Reduction Plans are already being excluded from NHS procurement opportunities.

EU Green Public Procurement (GPP) Criteria

The European Commission has developed Green Public Procurement criteria for several product categories, and healthcare-relevant criteria are expanding. While medical devices do not yet have a dedicated GPP product sheet, several related categories apply:

• Electrical and electronic equipment — Energy efficiency, recyclability, hazardous substance content
• Textiles (including surgical textiles) — Fiber origin, chemical content, durability
• Cleaning products — Environmental and health impact of cleaning and disinfection chemicals

EU Member States have varying levels of GPP adoption. The Netherlands, Sweden, Denmark, and Germany have among the most ambitious healthcare GPP programs. Several EU hospital networks now require suppliers to provide Environmental Product Declarations (EPDs) or lifecycle assessment data as part of tender submissions.

US Healthcare Green Procurement

In the United States, healthcare green procurement is primarily driven by voluntary programs and health system initiatives rather than federal mandates:

• Practice Greenhealth — The leading US organization for healthcare sustainability, Practice Greenhealth publishes sustainable procurement guides and operates the Greenhealth Exchange, a group purchasing platform that evaluates products on environmental criteria. Over 1,100 hospitals participate in Practice Greenhealth programs.
• Kaiser Permanente — One of the earliest healthcare systems to adopt environmentally preferable purchasing (EPP) policies. Kaiser evaluates medical products on chemical content, recyclability, packaging, and supplier environmental performance.
• Health Care Without Harm — An international coalition working to transform healthcare worldwide so that it reduces its environmental footprint. Their sustainable procurement resources help hospitals develop and implement green purchasing policies.
• Group Purchasing Organizations (GPOs) — Major GPOs including Vizient, Premier, and HealthTrust are increasingly incorporating sustainability metrics into their product evaluation and contracting processes.

Implications for Medical Device Manufacturers

The shift toward green procurement means that sustainability performance is becoming a commercial differentiator — not just a corporate responsibility exercise. Practical steps for device companies:

• Publish a Carbon Reduction Plan — Essential for UK market access and increasingly expected elsewhere
• Prepare Environmental Product Declarations — ISO 14025 Type III EPDs provide standardized, verified environmental data in a format procurement teams can evaluate
• Respond to sustainability questionnaires — Develop a centralized team or system to efficiently respond to the growing volume of sustainability data requests from customers
• Track and disclose Scope 3 emissions — Healthcare buyers increasingly expect product-level carbon footprint data, not just corporate-level disclosure
• Obtain third-party sustainability ratings — EcoVadis, CDP, and similar platforms are increasingly referenced in procurement criteria

Commercial reality: A 2024 Practice Greenhealth survey found that over 70% of US health systems consider environmental impact when making purchasing decisions. In the UK, the NHS's 10% sustainability weighting in procurement evaluations means that two otherwise equal bids will be decided on environmental performance. For medtech sales teams, sustainability data is no longer a nice-to-have appendix — it is a competitive weapon.

Right to Repair and Its Sustainability Implications

The right to repair movement — legislation and advocacy aimed at giving device owners and independent service providers access to the parts, tools, documentation, and software needed to repair products — has significant sustainability implications for the medical device industry.

Legislative Landscape

Right to repair legislation is advancing rapidly, particularly in the United States and Europe:

• United States — New York enacted the first comprehensive right to repair law (Digital Fair Repair Act) in 2022, followed by Minnesota (2023), Colorado (2024), Oregon (2024), and California (SB 44). California's law requires manufacturers to supply necessary tools, parts, software, and documentation for repairs for seven years after production. However, most US state laws currently exempt medical devices to preserve patient safety oversight.
• European Union — The EU Right to Repair Directive (2024) establishes requirements for manufacturers to provide repair services and spare parts for certain product categories at reasonable prices. While medical devices are not explicitly covered in the initial scope, the directive signals a clear regulatory trajectory toward broader repairability requirements.
• FDA position — A 2018 FDA report concluded that when hospitals have choices for servicing and parts, they enjoy competitive pricing, accountability, and in most cases better service. The FDA has generally supported the principle that device owners should have access to service information, though patient safety remains the overriding consideration.

Environmental Impact of Repair Restrictions

The medical equipment maintenance sector is valued at over $54 billion globally. When manufacturers restrict access to parts, tools, and service documentation, the consequences extend beyond cost:

• Premature disposal — Devices that could be repaired are instead discarded, contributing to electronic waste and resource depletion
• Reduced access — Developing countries and rural facilities cannot maintain equipment when OEM service is unavailable or unaffordable, leading to premature equipment retirement
• Supply chain dependency — Restriction of third-party repair increases dependency on global supply chains for replacement devices rather than local repair capabilities
• Waste generation — The inability to replace individual components forces whole-device replacement, dramatically increasing material consumption and waste

What This Means for Device Design

Manufacturers that embrace repairability gain both sustainability and commercial advantages:

• Modular design enables component-level replacement rather than whole-device disposal
• Published service manuals support longer device lifetimes and reduce waste
• Available spare parts extend useful life by years or decades for capital equipment
• Software update support prevents premature obsolescence of otherwise functional hardware
• Refurbishment programs (like those operated by Philips, Siemens Healthineers, and GE HealthCare) demonstrate that repairability and sustainability can be commercially viable business models

Strategic consideration: While patient safety concerns justify careful regulation of medical device repair, manufacturers that proactively embrace repairability — providing service documentation, maintaining spare parts availability, and designing for modularity — will be better positioned as right to repair legislation expands and healthcare systems increasingly value equipment longevity in procurement decisions.

ESG Reporting and Frameworks

For medtech companies subject to mandatory sustainability reporting — or those that choose to report voluntarily — several frameworks and standards provide structure.

GRI Standards

The Global Reporting Initiative (GRI) Standards are the most widely used sustainability reporting framework globally. GRI provides universal standards (governance, strategy, stakeholder engagement), topic-specific standards (emissions, waste, water, labor practices, human rights), and sector-specific guidance. GRI reporting follows a modular structure: companies select the topics material to their business and report against the corresponding standards.

ISSB/IFRS S1 and S2

The International Sustainability Standards Board (ISSB), established by the IFRS Foundation, has issued IFRS S1 (General Requirements for Disclosure of Sustainability-related Financial Information) and IFRS S2 (Climate-related Disclosures). These standards are designed for investor-focused reporting and are being adopted or endorsed by jurisdictions worldwide, including the UK, Japan, Singapore, Australia, and Brazil. ISSB standards incorporate and supersede the former SASB Standards and TCFD Recommendations.

For medtech, the SASB Medical Equipment & Supplies standard (now part of the ISSB framework) identifies specific disclosure topics including:

• Affordability and pricing
• Product safety
• Ethical marketing
• Supply chain management
• Business ethics

CDP Disclosure

The Carbon Disclosure Project (CDP) operates the global disclosure system for environmental data. CDP questionnaires cover climate change, water security, and forests. Over 23,000 companies disclosed through CDP in 2025. For medtech companies, CDP disclosure serves dual purposes: it satisfies investor information needs and generates data that feeds into CSRD and other regulatory reporting.

Practical ESG Metrics for MedTech

Category	Metric	Unit	Data Source
Climate	Scope 1 GHG emissions	tCO2e	Direct measurement, fuel records
Climate	Scope 2 GHG emissions	tCO2e	Electricity bills, emission factors
Climate	Scope 3 GHG emissions	tCO2e	Supplier data, spend-based models
Energy	Total energy consumption	MWh	Utility records
Energy	Renewable energy percentage	%	PPA records, REC certificates
Water	Total water withdrawal	m3	Water bills, meter readings
Waste	Total waste generated	metric tons	Waste hauler records
Waste	Waste diverted from landfill	%	Recycling/recovery records
Materials	Recycled content in products	% by weight	Bill of materials analysis
Products	Devices with lifecycle assessment	count or %	Internal program tracking
Supply chain	Suppliers assessed for environmental criteria	% of spend	Supplier management system

UN Sustainable Development Goals Alignment

Many medtech companies map their sustainability initiatives to the UN Sustainable Development Goals (SDGs). The most relevant SDGs for the medical device industry include:

• SDG 3 — Good Health and Well-Being (core to the industry's mission)
• SDG 6 — Clean Water and Sanitation (water stewardship in manufacturing)
• SDG 7 — Affordable and Clean Energy (renewable energy adoption)
• SDG 8 — Decent Work and Economic Growth (supply chain labor standards)
• SDG 9 — Industry, Innovation and Infrastructure (sustainable innovation)
• SDG 12 — Responsible Consumption and Production (circular economy, waste reduction)
• SDG 13 — Climate Action (emissions reduction, climate risk management)

Case Studies: Industry Leaders

Medtronic

Medtronic, the world's largest pure-play medical device company, has one of the most comprehensive sustainability programs in the industry:

• Committed to achieving carbon neutrality in operations (Scope 1 and 2) by 2030 and net zero across the full value chain by 2045
• Joined RE100, committing to 100% renewable electricity
• Reduced absolute Scope 1 and 2 emissions by over 40% from their 2020 baseline
• Implemented product lifecycle assessments across major product lines
• Launched packaging sustainability initiatives reducing packaging volume and transitioning to recyclable materials
• Published detailed ESG reports following GRI, SASB, and TCFD frameworks

Philips — Circular Economy Pioneer

Philips has positioned itself as the leading circular economy advocate in healthcare technology:

• Generated EUR 2.1 billion in circular revenue in 2024 (refurbished equipment, services, software, reconditioned products)
• Operates Diamond Select refurbished equipment program, extending the life of imaging systems, patient monitors, and other capital equipment
• Targets 25% of revenue from circular products, services, and solutions by 2025 (largely achieved)
• Redesigned products for repairability and upgradability — modular MRI coils, upgradable software platforms, refurbishable ultrasound transducers
• Achieved zero waste to landfill at multiple manufacturing sites
• Uses 100% renewable electricity across all global operations

Johnson & Johnson — Health for Humanity

Johnson & Johnson's MedTech segment (formerly Ethicon, DePuy Synthes, and other businesses) operates under the company's broader ESG framework:

• Committed to carbon neutrality across operations by 2030 (achieved Scope 1 and 2 carbon neutrality in 2023 using a combination of renewables, efficiency, and carbon offsets)
• Implemented Earthwards program — an internal eco-design standard that evaluates products across seven sustainability impact areas (materials, packaging, energy, waste, water, social, and innovation). Over 120 products have been Earthwards-recognized.
• Invested in alternative sterilization technologies to reduce EtO dependency
• Published detailed CDP disclosures, achieving A-list scores for climate and water security

BD (Becton, Dickinson and Company)

BD has implemented targeted sustainability programs relevant to its product portfolio of syringes, needles, catheters, and diagnostic systems:

• Set science-based targets validated by the Science Based Targets initiative (SBTi) for Scope 1, 2, and 3 emission reductions
• Launched the BD Recycle Program for sharps containers, enabling recycling rather than incineration of used sharps disposal containers
• Implemented PVC-free alternatives in several IV product lines
• Published comprehensive ESG reports using GRI standards
• Committed to water neutrality in water-stressed regions

Smaller MedTech Examples

Sustainability is not only for large multinational corporations. Smaller medtech companies are also making progress:

• Ambu (single-use endoscopes) has published lifecycle assessments comparing their single-use endoscopes to reprocessed reusable scopes, finding comparable or lower carbon footprints when reprocessing water and energy are included
• Nanosonics (trophon device disinfection system) has marketed the environmental advantages of its hydrogen peroxide-based ultrasound probe disinfection versus high-level disinfectant chemicals
• Penumbra has implemented ISO 14001 environmental management systems at its manufacturing sites
• Multiple startups are developing biodegradable surgical tools, compostable packaging, and recyclable device components, though most remain in early commercialization stages

Greenwashing Risks

As sustainability becomes commercially valuable, the risk of greenwashing — making misleading or unsubstantiated environmental claims — increases. In medtech, greenwashing carries both reputational and regulatory consequences.

What Constitutes Greenwashing in MedTech

Common greenwashing patterns in the medical device industry:

• Vague claims — Labeling a device as "eco-friendly" or "green" without specific, measurable, verifiable data
• Irrelevant claims — Highlighting compliance with regulations that are already mandatory (e.g., "RoHS compliant!" for a device class where RoHS is legally required)
• Hidden trade-offs — Promoting one environmental benefit while ignoring a larger negative impact (e.g., marketing reduced packaging weight while ignoring that the device itself is single-use and non-recyclable)
• Cherry-picked metrics — Reporting only favorable sustainability metrics while omitting unfavorable ones
• Unverified claims — Making sustainability claims without third-party verification or supporting data
• Carbon offset reliance — Claiming "carbon neutrality" based primarily on offset purchases rather than actual emission reductions

Regulatory Consequences

The EU Green Claims Directive (proposed) would require companies to substantiate environmental claims with lifecycle assessment data and third-party verification before making them publicly. The US Federal Trade Commission's Green Guides (16 CFR Part 260) provide guidance on environmental marketing claims and the FTC has enforcement authority over deceptive practices.

In 2025, the EU Empowering Consumers Directive entered into force, prohibiting generic environmental claims (such as "eco-friendly" or "green") unless backed by recognized certification or specific evidence.

Making Defensible Sustainability Claims

To avoid greenwashing:

• Use specific, quantified claims — "This device uses 30% less plastic than the previous generation" is defensible; "eco-friendly device" is not
• Conduct lifecycle assessments — Base claims on ISO 14040/14044 compliant LCA, not assumptions
• Obtain third-party verification — Use recognized certifications (ISO 14001, ISO 14064, EcoVadis, B Corp) and third-party assurance for ESG data
• Report limitations — Acknowledge trade-offs and areas where improvement is still needed
• Follow the GHG Protocol — For any climate-related claims, follow established accounting methodologies
• Document everything — Maintain complete records supporting every public sustainability claim

Implementation Roadmap

For medtech companies beginning or accelerating their sustainability journey, a phased approach balances ambition with practicality.

Phase 1: Foundation (0-6 Months)

Quick wins that build momentum and baseline data:

• Conduct an energy audit of all manufacturing facilities — identify the top 10 energy consumers and implement no-cost/low-cost efficiency measures (LED lighting, compressed air leak repairs, HVAC setpoint optimization)
• Complete a Scope 1 and 2 GHG inventory using the GHG Protocol Corporate Standard
• Conduct a waste audit — categorize waste streams, identify recycling opportunities, establish waste diversion targets
• Review packaging across top-selling products — identify immediate right-sizing and material reduction opportunities
• Establish a sustainability governance structure — appoint a sustainability lead, form a cross-functional sustainability committee (R&D, operations, supply chain, regulatory, marketing, finance)
• Benchmark against peers using publicly available ESG reports and ratings

Phase 2: Strategic Development (6-18 Months)

Medium-term initiatives that require investment and cross-functional coordination:

• Develop and publish a sustainability strategy and targets aligned with business strategy
• Conduct lifecycle assessments for the top 5-10 products by revenue — identify hotspots and prioritize improvement areas
• Begin Scope 3 emissions estimation — start with purchased goods/services (Category 1) and use of sold products (Category 11)
• Integrate sustainability criteria into design controls — add environmental requirements to design input reviews, include LCA checkpoints in the design process
• Implement ISO 14001 (Environmental Management System) at key manufacturing sites — this provides the management system framework for systematic environmental improvement
• Launch supplier sustainability engagement — issue supplier sustainability questionnaires, set expectations, and begin tracking supplier environmental performance
• Initiate renewable energy procurement — evaluate on-site solar, PPAs, and other options based on facility locations and energy markets
• Evaluate sterilization alternatives for product lines currently using EtO — assess feasibility of e-beam, gamma, or other methods

Phase 3: Transformation (18-36+ Months)

Long-term strategic shifts that fundamentally change the business model:

• Set and publish science-based targets (SBTi-validated) for Scope 1, 2, and 3 emissions
• Achieve ISO 50001 energy management certification at all major manufacturing sites
• Redesign products for circularity — modular architectures, design for disassembly, reusable/refurbishable platforms
• Implement product take-back and recycling programs for priority product lines
• Achieve 100% renewable electricity across operations
• Publish CSRD-compliant sustainability reports (or equivalent for non-EU companies)
• Achieve third-party ESG ratings at leadership level (CDP A-list, EcoVadis Gold/Platinum)
• Integrate sustainability metrics into executive compensation and performance management

Building the Business Case

Sustainability investments require financial justification. Key value drivers for the business case:

Value Driver	Quantification Approach
Energy cost savings	Calculate annual savings from efficiency measures and renewable energy procurement
Waste disposal cost reduction	Reduced landfill/incineration fees from waste diversion
Material cost reduction	Less material per device, recycled content at lower cost
Revenue protection	Contract wins/losses based on sustainability criteria in procurement
Regulatory compliance cost avoidance	Cost of CSRD compliance vs. penalties for non-compliance
Risk mitigation	Avoided costs from supply chain disruptions, regulatory enforcement, reputation damage
Capital access	Lower cost of capital from improved ESG ratings
Talent retention	Reduced recruitment and turnover costs

ROI reality: Most energy efficiency investments have payback periods of 1-3 years. Renewable energy procurement through PPAs often achieves cost parity or savings compared to conventional electricity. Waste reduction and yield improvement generate ongoing savings. The biggest challenge is not ROI — it is getting started, overcoming organizational inertia, and maintaining momentum.

Frequently Asked Questions

Is sustainability reporting mandatory for medical device companies?

It depends on jurisdiction and company size. In the EU, the CSRD makes sustainability reporting mandatory for companies above certain thresholds (250+ employees and EUR 50M+ revenue or EUR 25M+ assets). In the US, California SB 253 requires GHG emissions disclosure for companies with $1B+ revenue. SEC rules require climate disclosure for public companies. Even if your company is below these thresholds, customers, investors, and supply chain partners will increasingly require sustainability data.

Does EU MDR require environmental sustainability consideration in device design?

Not as an explicit "sustainability" requirement, but several Annex I GSPRs are relevant. GSPR 10.4 restricts hazardous substances (CMR substances, endocrine disruptors). GSPR 14.7 requires disposal information. The broader EU regulatory ecosystem (REACH, RoHS, CSRD, ESPR) creates additional environmental obligations for devices placed on the EU market.

How do I calculate the carbon footprint of a medical device?

Conduct a lifecycle assessment following ISO 14040/14044 and ISO 14067. Define the functional unit, system boundaries (ideally cradle-to-grave), and collect data on materials, energy, transportation, use phase, and end-of-life. Use LCA software (openLCA, SimaPro, GaBi) and lifecycle inventory databases (ecoinvent, USLCI). For product comparisons, ensure consistent system boundaries and functional units.

Can single-use devices ever be "sustainable"?

Single-use devices can be made more sustainable — through material reduction, use of recycled or bio-based materials, packaging optimization, and choice of sterilization method — but they will inherently have a higher per-use environmental impact than well-designed reusable alternatives. The infection control benefits of single-use must be weighed against the environmental costs. Hybrid designs (single-use patient-contact components with reusable handles/electronics) represent a middle ground.

What is the FDA's position on reprocessing single-use devices?

The FDA supports and regulates reprocessing of single-use devices. Reprocessors must comply with the same requirements as original equipment manufacturers — including 510(k) or PMA submissions, QSR/QMSR compliance, adverse event reporting, and labeling requirements. The FDA has cleared reprocessing for numerous device categories. The original manufacturer is not liable for the performance of a reprocessed device.

How does the ESPR Digital Product Passport apply to medical devices?

Currently, medical devices covered by EU MDR/IVDR are conditionally exempt from ESPR requirements for aspects already addressed by those regulations. However, the Digital Product Passport concept may eventually apply to medical devices through future amendments or delegated acts. Companies should monitor developments and begin collecting the types of data (material composition, recyclability, carbon footprint) that a DPP would require.

What sterilization method has the lowest environmental impact?

Vaporized hydrogen peroxide (VHP) has the lowest direct environmental impact — its byproducts are water and oxygen. However, VHP has significant material compatibility limitations and lower throughput. E-beam and X-ray sterilization have low direct emissions but high electricity consumption. Steam autoclaving is energy and water-intensive. No single method is environmentally superior for all devices. The optimal choice depends on device materials, geometry, bioburden, packaging, and throughput requirements.

How do I get started with ESG reporting if my company has never done it?

Start with a materiality assessment — identify which ESG topics are most significant for your business and stakeholders. Then establish baseline measurements for key metrics: Scope 1 and 2 GHG emissions, energy consumption, water usage, waste generation, and workforce demographics. Use the GRI Standards as a reporting framework (they are free and widely recognized). Publish an initial report that is honest about where you stand and where you intend to go. You do not need to have all the answers in year one — stakeholders value transparency and a credible improvement trajectory.

What are science-based targets and should my medtech company set them?

Science-based targets (SBTs) are greenhouse gas emission reduction targets aligned with what climate science says is necessary to meet the goals of the Paris Agreement (limiting global warming to 1.5 degrees C or well below 2 degrees C). The Science Based Targets initiative (SBTi) provides frameworks, validation, and tracking. Setting SBTs signals credible commitment to climate action. Over 50 healthcare and medtech companies have SBTi-validated targets. If your company is publicly traded, has significant operations in the EU, or sells to sustainability-conscious health systems, SBTs are increasingly expected rather than optional.

How do conflict minerals regulations affect medical device companies?

Medical devices frequently contain tantalum (capacitors), tin (solder), tungsten (cutting instruments, counterweights), and gold (connectors, sensors). US SEC-registered companies must file Form SD and conduct due diligence on the origin of 3TG minerals. EU importers above specified thresholds must comply with the EU Conflict Minerals Regulation. Even companies not directly subject to these regulations receive due diligence requests from customers. Establish a conflict minerals program, map your supply chain, use the Conflict Minerals Reporting Template (CMRT) from the Responsible Minerals Initiative, and engage suppliers on responsible sourcing.

Does the WEEE Directive apply to medical devices?

Yes. The WEEE II Directive (2012/19/EU) brought medical devices and IVDs within scope. Manufacturers of electronic medical devices must register with national WEEE compliance schemes, contribute to collection and recovery targets, and design products for easier recycling. There are limited exemptions for active implantable devices and devices expected to be infective prior to end of life. The vast majority of electronic medical devices — monitors, imaging systems, pumps, analyzers — are fully within scope. WEEE compliance requires coordination with national compliance schemes in each EU Member State where products are sold.

What are the NHS net zero requirements for medical device suppliers?

The NHS has progressively tightened sustainability requirements for all suppliers. Since April 2024, all NHS procurements (regardless of size) require suppliers to publish a Carbon Reduction Plan covering UK Scope 1, 2, and partial Scope 3 emissions. By April 2027, suppliers must cover global Scope 1, 2, and 3 emissions. By April 2028, product-level carbon footprinting will be required. A minimum 10% sustainability weighting applies to all procurement evaluations. Medical device companies without a published CRP are being excluded from NHS tenders.

How does right to repair legislation affect medical device manufacturers?

Several US states have enacted right to repair laws (New York, Minnesota, Colorado, Oregon, California), though most currently exempt medical devices. The EU Right to Repair Directive (2024) similarly signals a trajectory toward broader repairability requirements. While exemptions protect patient safety, the direction of travel is clear: manufacturers should design for repairability, maintain spare parts availability, and provide service documentation. Companies that embrace repairability gain sustainability advantages (longer device lifetimes, less waste) and commercial advantages (customer loyalty, alignment with procurement trends favoring equipment longevity).

What can device manufacturers do about operating room waste?

Operating rooms generate over 30% of hospital waste and two-thirds of regulated medical waste. Up to 74% of OR waste is potentially recyclable but typically ends up in high-cost regulated waste streams. Device manufacturers can help by: designing packaging for recyclability, offering modular surgical kits to reduce unused items, supporting preference card optimization to eliminate routinely opened but unused devices, providing take-back or recycling programs for device packaging (especially blue wrap), and designing devices with clearly marked and easily separable materials for end-of-life sorting.

Conclusion: Sustainability as Competitive Advantage

The medical device industry stands at an inflection point. Sustainability and ESG are transitioning from voluntary commitments to regulatory mandates, procurement requirements, and investor expectations. Companies that build sustainability into their products, operations, and supply chains now will be better positioned for the regulatory landscape of the next decade — and will gain competitive advantages in procurement, talent acquisition, cost efficiency, and brand reputation.

The path forward does not require perfection. It requires honest measurement, credible targets, systematic improvement, and transparent reporting. Start with what you can measure, improve what you can control, and collaborate with your value chain on the rest. The companies that treat sustainability as a strategic capability — not a compliance burden — will define the next era of medical technology.